An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma
| Sponsored by: | AstraZeneca |
| Information provided: | AstraZeneca |
| ClinicalTrials.gov Identifier: | NCT00597116 |
Purpose:
A clinical study to assess if a new investigational drug is effective in treating malignant mesothelioma, compared to a chemotherapy treatment (Navelbine®). In this study the patients will be assigned by chance to receive either the new drug or a chemotherapy treatment (Navelbine®). Treatment will continue as long as the cancer does not worsen and the patient wishes to continue in the study. The study will recruit approximately 66 patients.
| Condition | Intervention | Phase |
|
Mesothelioma |
Drug: Vinorelbine Drug: Vandetanib |
Phase 2 |
Eligibility
Study Design: Allocation: Randomized, Control: Active Control, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Official Title: A Randomized Phase II Trial To Evaluate The Efficacy And Safety Of Vandetanib (ZD6474, ZACTIMA ™) Versus Vinorelbine In Patients With Inoperable Or Relapsed Malignant Mesothelioma.
Enrollment Size: Both
Gender: 18 Years
Min. Age: N/A
Max. Age: No
Location and Contact Information
, Germany
Research Site, Essen, Germany, ,
Status:
, Germany
Research Site, Halle-Dolau, Germany, ,
Status:
, Germany
Research Site, Hamburg, Germany, ,
Status:
, Germany
Research Site, Heidelberg, Germany, ,
Status:
, Switzerland
Research Site, Chur, Switzerland, ,
Status:
, Switzerland
Research Site, Zurich, Switzerland, ,
Status:
Last modified: July 29 2010.
